Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ARK Genomic Revolution ETF (NY: ARKG )

24.66 +0.48 (+1.99%)
Official Closing Price Updated: 4:10 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ARK Genomic Revolution ETF

< Previous 1 2 3 4 5 6 7 8 9 Next >
Cathie Wood Trims Pfizer Stake And Loads Up $25M In Rival COVID-19 Vaccine Maker
Cathie Wood led Ark Invest on Wednesday initiated a position in Moderna Inc (NASDAQ: MRNA) after the biotech company said an updated version of its COVID-19 booster vaccine appeared to provide strong 
Via Benzinga
Cathie Wood Is Selling Gene Editing Stocks. Here’s Why.
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves? 
Via InvestorPlace
Know The 2 Healthcare Companies Cathie Wood's Ark Invest Bought On Friday
Cathie Wood's Ark Invest may have had a disappointing 2021, but the fund's purchases/liquidations are always watched keenly by investors. On Friday, ETFs managed by... 
Via Benzinga
Tesla Bull Cathie Wood Bought $1M Shares In This Biotech Stock Today
Tesla Inc (NASDAQ: TSLA) bull Cathie Wood led Ark Investment Management on Thursday further raised its exposure in China-based biotech company Burning Rock Biotech Ltd (NASDAQ: BNR). 
Via Benzinga
4 Big Ark Innovation Components Report Earnings This Week: Could It Spell More Danger For Cathie Wood?
The Ark Funds ETFs have been hit hard in 2022 with growth stocks among the laggards as investors turned to value stocks. Many stockholders have begun to question ... 
Via Benzinga
A Leaky ARKK
In a year when everything skyrocketed to nauseating highs, Cathie’s momentum-obsessed investing style was a dud. 
Via Talk Markets
Neck Cream Reversal
Cathie Wood's ARKG is down about 50% over the past 9 months. 
Via Talk Markets
Psyched: Cathie Wood Invests In Psychedelics Co ATAI, Bill Approved in Utah, AI Startup To 'Design States Of Mind'
The psychedelics sector received its latest sign of acceptance from Wall Street with famed investor Cathie Wood taking a position ... 
Via Benzinga
Cathie Wood Is Buying this Peter Thiel-Backed Psychedelics Stock For Ark Funds
There’s a new psychedelics company being added to an ETF from Cathie Wood. What Happened: The Ark Genomic Revolution ETF (BATS: ARKG) took an initial position in shares of... 
Via Benzinga
Cathie Wood's Ark Invest Sheds Stake In This Large-Cap Pharma Ahead Of Earnings
Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed. 
Via Benzinga
Ark Funds Launching New Fund That Could Invest In Private Companies
One of the biggest and most well-known ETF companies is launching a new closed-end fund that provides major differences from its existing ETFs. 
Via Talk Markets
Ark Funds Launching New Fund That Could Invest In Private Companies
One of the biggest and most well-known ETF companies is launching a new closed-end fund that provides major differences from its existing ETFs.... 
Via Benzinga
Small Cap Biotech Stocks: Is it time to start trading?
It’s time to trade beaten-up small cap biotech stocks. 
Via Talk Markets
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?
One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t... 
Via Benzinga
UiPath Stock Is Worth Believing in Here as Wood Holds Fast
Cathie Woods ARK Investment ETFs have loaded up on shares of UiPath despite the decline. PATH stock has plenty of upside from here. 
Via InvestorPlace
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
Cathie Wood Added To Stake In This Medical Technology Company As Its Shares Surged 6% On Friday
Cathie Wood’s Ark Investment Management on Friday bought 26,126 shares — estimated to be worth $163,026 — in Quantum-Si Inc (NASDAQ: QSI). Shares of the medical... 
Via Benzinga
Biotech Playbook 2021: No Help From Small Caps In Q4
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
Bionano Genomics Proves Not Everything Genetic is Gold
Bionano sells a $150,000 machine called Saphyr that does genetic mapping. It's a solid device, but its future remains in the future, as do BNGO stock fortunes. 
Via InvestorPlace
Cathie Wood Testing 'ARK On Steroids' As ARK Funds Struggle
Wood said ARK is testing a strategy to short stocks in the big benchmark indexes, 
Via Investor's Business Daily
Topics Electric Vehicles
Exposures Electric Vehicles
Don't Look Now, But Cathie Wood's Ark Is Taking On Water
Among the biggest losers over the last 48 hour tech stock volatility has been...well, everything in Cathie Wood's 
Via Talk Markets
Biotech Stocks are Due for a Rally
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums. 
Via Talk Markets
Yes, Cathie Wood's $700,000 Bitcoin Price Prediction Is Legit
A Bitcoin price prediction of $700,000 - more than 10 times the recent price - would strike most people as delusional. But this eye-popping target doesn't come from a Bitcoin fan. It comes from Wall... 
Via Talk Markets
Tesla (TSLA) Not Enough To Lift ARK Innovation (ARKK)
An updated look at Cathie Wood’s ARK ETFs relative strength versus the S&P 500 SPY ETF. 
Via Talk Markets
Topics Stocks
Exposures US Equities
ETF Battles: Finding the Top Genomics Biotech ETF – A Triple Header of ARKG vs IDNA vs GNOM
The search for therapies tackling chronic illnesses like cancer, diabetes, and heart disease has put stocks in the biotechnology and genomics industry sector on center stage. 
Via Talk Markets
Ginkgo Bioworks Stock Drops 20% After Short Sellers Call Company A 'Colossal Scam'
Shares of synthetic biology company Ginkgo Bioworks Holdings Inc (NYSE: 
Via Benzinga
Mike Khouw Sees Unusual Options Activity In ARK Genomic Revolution ETF
On CNBC's "Options Action," Mike Khouw said ARK Genomic Revolution ETF (BATS: ARKG) was active on Tuesday as it traded six times its average daily put volume.... 
Via Benzinga
Biotech Playbook Revisited As Technicals Weaken
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still... 
Via Talk Markets
Look For The Q4 Biotech Bounce In Mid-Small Caps
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best... 
Via Talk Markets
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.